Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer

European Urology

Volumn 68, Issue 1, 2015, Pages 139-146

  Nordström, Tobias ^a,b   Vickers, Andrew ^c   Assel, Melissa ^c   Lilja, Hans ^c,d,e   Grönberg, Henrik ^b   Eklund, Martin ^b,f  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarkers; Kallikrein related peptidases; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; (-2)PRO-PROSTATE-SPECIFIC ANTIGEN, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROTEIN PRECURSOR; TISSUE KALLIKREIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CALIBRATION; CANCER RISK; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; FOUR KALLIKREIN PANEL; GENITAL SYSTEM DISEASE ASSESSMENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; RECEIVER OPERATING CHARACTERISTIC; AGE; AREA UNDER THE CURVE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

AGE FACTORS; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TISSUE KALLIKREINS;

EID: 84942991529     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.010     Document Type: Article

References (25)

1. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostatespecific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
2. Anderson JR, Strickland D, Corbin D, Byrnes JA, Zweiback E. Agespecific reference ranges for serum prostate-specific antigen. Urology 1995;46:54-7.
3. Jacobsen SJ, Bergstralh EJ, Guess HA, et al. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med 1996;156:2462-8.
4. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 2009;9:14.
5. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013;346:f2023.
6. Hori S, Blanchet J-S, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2013;112:717-28.
7. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011;185:1650-5.
8. Stephan CC, Vincendeau SS, Houlgatte AA, Cammann HH, Jung KK, Semjonow AA. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2012;59:306-14.
9. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66.
10. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011;60:214-22.
11. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 2013;63:986-94.
12. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
13. Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232-9.
14. Vickers AJ, Gupta A, Savage CJ, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2011;20:255-61.
15. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Gö teborg, Sweden. BMC Medicine 2008;6:19.
16. Benchikh A, Savage C, Cronin A, et al.Apanel of kallikreinmarkers can predict outcome of prostate biopsy following clinical work-up: an independent validation study fromthe European Randomized Study of Prostate Cancer Screening, France. BMC Cancer 2010;10:635.
17. Vä isänen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab0) 2 fragments. Anal Chem 2006;78:7809-15.
18. Nordström T, Aly M, Clements MS, Weibull CE, Adolfsson J, Grönberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013;63:419-25.
19. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 2009;48:27-33.
20. DeLong ERE, DeLong DMD, Clarke-Pearson DLD. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
21. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74.
22. Jansen FH, van Schaik RHN, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
23. Team RDC. R: a language and environment for statistical computing. R Foundation for Statistical Computing Web site. http://www.R-project.org/.
24. Hybritech p2PSA draft directional insert. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/cdrh-docs/pdf9/P090026c.pdf.
25. Carroll P, Kellogg Parsons J, Andriole GL, et al. Prostate cancer early detection. Fort Washington, PA: National Comprehensive Cancer Network; 2014:1-35.